Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 12;13(1):204.
doi: 10.3390/nu13010204.

An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health

Andrew Elagizi  1 , Carl J Lavie  1 , Evan O'Keefe  2 , Keri Marshall  3 , James H O'Keefe  4 , Richard V Milani  1
Affiliations
Review

An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health

Andrew Elagizi et al. Nutrients. .

Abstract

Interest in the potential cardiovascular (CV) benefits of omega-3 polyunsaturated fatty acids (Ω-3) began in the 1940s and was amplified by a subsequent landmark trial showing reduced CV disease (CVD) risk following acute myocardial infarction. Since that time, however, much controversy has circulated due to discordant results among several studies and even meta-analyses. Then, in 2018, three more large, randomized trials were released-these too with discordant findings regarding the overall benefits of Ω-3 therapy. Interestingly, the trial that used a higher dose (4 g/day highly purified eicosapentaenoic acid (EPA)) found a remarkable, statistically significant reduction in CVD events. It was proposed that insufficient Ω-3 dosing (<1 g/day EPA and docosahexaenoic acid (DHA)), as well as patients aggressively treated with multiple other effective medical therapies, may explain the conflicting results of Ω-3 therapy in controlled trials. We have thus reviewed the current evidence regarding Ω-3 and CV health, put forth potential reasoning for discrepant results in the literature, highlighted critical concepts such as measuring blood levels of Ω-3 with a dedicated Ω-3 index and addressed current recommendations as suggested by health care professional societies and recent significant scientific data.

Keywords: cardiovascular disease; omega 3 index; omega 3 polyunsaturated fatty acid.

PubMed Disclaimer

Conflict of interest statement

J.O. is Chief Medical Officer and founder of CardioTabs, a nutraceutical company, and has a major ownership interest in the company. CardioTabs sells products that contain omega-3. Lavie is a speaker and consultant for Amarin on Vascepa and for DSM Nutritional Products and for the Global Organization for EPA and DHA Omega-3s. Marshall is Director of Medical and Scientific Communications for Pharmavite, a company that produces and markets omega-3 products. A.E., E.O. and R.V.M. report no potential conflicts of interest.

Figures

Figure 1
Figure 1
Pooled results from meta-analysis. This figure showed the pooled estimate of relative risk and 95% CI, as well as the number of studies and combined number of participants. CHD = coronary heart disease; CVD = cardiovascular disease; MI = myocardial infarction. Reproduced with permission from: Bernasconi, A.A., Wiest, M.M., Lavie, C.J., Milani, R.V., Laukkanen, J.A. Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. Mayo. Clin. Proc. 2020; S0025-6196(20)20985-X.
Figure 2
Figure 2
Dose–effect relationship for the prevention of CVD events. The horizontal axis shows the EPA + DHA dosage in grams per day. The vertical axis shows the treatment effect (log-relative risk). The area of each study square is proportional to its regression weight (inverse-variance of relative risk estimate). Reproduced with permission from: Bernasconi, A.A., Wiest, M.M., Lavie, C.J., Milani, R.V., Laukkanen, J.A. Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. Mayo. Clin. Proc. 2020; S0025-6196(20)20985-X.
Figure 3
Figure 3
Hypothetical omega-3 supplementation dose and threshold effect.
See this image and copyright information in PMC

References

    1. Sinclair H.M. The Diet of Canadian Indians and Eskimos. Proc. Nutr. Soc. 1953;12:69–82. doi: 10.1079/PNS19530016. - DOI
    1. Bang H.O., Dyerberg J. Plasma Lipids And Lipoproteins In Greenlandic West Coast Eskimos. Acta Med. Scand. 1972;192:85–94. doi: 10.1111/j.0954-6820.1972.tb04782.x. - DOI - PubMed
    1. Lavie C.J., Milani R.V., Mehra M.R., Ventura H.O. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. J. Am. Coll. Cardiol. 2009;54:585–594. doi: 10.1016/j.jacc.2009.02.084. - DOI - PubMed
    1. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011;58:2047–2067. doi: 10.1016/j.jacc.2011.06.063. - DOI - PubMed
    1. De Caterina R. Drug therapy: N-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 2011;364:2439–2450. doi: 10.1056/NEJMra1008153. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources